Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Bioniche de reïncarnatie van Crucell:) ?

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Bioniche de reïncarnatie van Crucell:) ?

79 Posts
Pagina: «« 1 2 3 4 | Laatste | Omlaag ↓
  3. [verwijderd] 23 november 2010 09:14
    quote:

    pardon schreef:

    Bij Crucell drukte ze ook 18 miljoen aandelen bij om J&J een plezier te doen,en na een jaar is het bod daar.
    Dat kan ook bij bioniche life gebeuren.
    Crucell gaf 14,6 mio aandelen uit aan J&J, voor een prijs van € 20,50 p/a ongeveer. De koers stond op dat moment flink lager.

    BNC drukt er 20 mio bij voor een prijs van AUD=+/-CAD 1,50, de koers stond op dat moment flink hoger.
  4. [verwijderd] 24 november 2010 14:06
    tophound, toen CRXL die aandelen verkocht aan JJ stonden ze er heel anders voor als BNC. BNC kan exploderen of imploderen in de komende 24 maanden.. de risk/reward voor de grote beleggers zit veel verder uit elkaar met BNC. CRXL was in die tijd al lang stabiel.

    aan het koers gedrag af te lezen samen met de nieuwe financiering.. lijkt bijna tijd om te kopen. als de bredere markt nog een paar klappen krijgt stap ik ergens rond de 1.4 in. zo niet wacht ik nog af.

    ben zelf geen biotech ster wat betreft diepgaand inzicht in de technologie. BNC ziet er momenteel goed uit, maar zeker van de zaken ben ik niet. dank voor alle informatie hier.
  6. [verwijderd] 24 november 2010 15:00
    >>Mijn bedoeling was aan te geven waarom de koers van BNC met de nieuwe emissie naar beneden duikelde, en die van CRXL niet.

    En mijn punt is dat CRXL toen al in een redelijke macht positie stond. BNC nog helemaal niet. Te veel risico voor de grote jongens nog. Vandaar de discount. Maar we snappen elkaar.

    Waar ik wel nerveus voor ben is handelen in een aandeel met zo weinig omzet. In de 6 maanden dat ik mee kijk is de handel al 2x stil gezet om bijna niks. Als het dus fout gaat ergens in de toekomst dan gaat het goed fout.. met weinig kans om er uit te springen zonder groot verlies.

  7. [verwijderd] 30 november 2010 21:35

    Bioniche Obtains Exclusive U.S. Rights to Equine Reproductive Product from CreoSalus


    BELLEVILLE, ON, Nov. 30 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, today announced that it has signed an agreement with Thorn BioScience LLC, a subsidiary of CreoSalus, Inc. The agreement provides exclusive rights to Bioniche to market and distribute CreoSalus' SucroMateTM Equine product in the U.S., with a first right of negotiation to expand the territory.

    SucroMateTM Equine was just registered in the U.S. by the U.S. Food and Drug Administration (FDA), one of only 8 new FDA-approved animal health drugs in 2010. It is a controlled release injectable of deslorelin acetate, used to time ovulation in horses and increasing the likelihood of conception during breeding. This is particularly valuable for thoroughbred horses where natural breeding is utilized, and it is also used in mares inseminated with fresh, cooled, and frozen semen.

    "This product is a natural fit with the Bioniche Animal Health portfolio of reproductive products for large animals, including horses," said Jim Phillips, President of Bioniche Animal Health (global). "The Company sells a portfolio of equine products in the U.S. market, and SucroMate; TM Equine will be a welcome addition to our offerings to equine veterinarians. SucroMate™ Equine particularly fits with our equine mycobacterial cell wall product - SettleTM - a fast-acting, intrauterine or intravenous endometritis therapy for broodmares."

    CreoSalus Co-Founder, Barry Simon, DVM, said, "Over a decade of research and development has been devoted to develop a platform technology that delivers peptides on a sustained release. SucroMateTM Equine is the first application of the technology. It delivers a stable, sterile, and consistent dosage of deslorelin for mare ovulation. FDA approval of SucroMateTM Equine provides veterinarians and horse owners with confidence in breeding their mares. Horsemen will no longer need to rely on compounded products that may not meet specifications or work properly."

    An estimated 250,000 to 300,000 mares are bred each year in the United States. Successful foaling is often a challenge due to mistimed breeding or to other health complications such as endometritis. Bioniche is pleased to offer registered products that help equine veterinarians address these challenges. SucroMateTM Equine will be available for the start of the 2011 breeding season in February, 2011.

    About CreoSalus, Inc.

    CreoSalus, Inc. is a privately held Louisville, Kentucky-based life sciences company specializing in the development and manufacturing of finished drugs, fine chemicals, and human medical devices. The Company's three operating businesses all relating to peptides are Advanced ChemTech (fine chemicals), Occam Design (human medical devices) and Thorn BioScience (finished drugs). Thorn BioScience's products include FDA-approved SucroMateTM Equine and SucroMateTM Porcine (under development) that regulate the ovulation in mares and sows, respectively
  8. [verwijderd] 6 december 2010 15:16
    Hoe gaat de koers straks bij opening op onderstaand bericht reageren, ik gok op een plus van een procent of 5.


    Bioniche, Through Distributor, Provides Exclusive Supply to Angus Association in Australia


    -Bayer Animal Health enters exclusive supply agreement for Bioniche reproductive products-

    BELLEVILLE, ON, Dec. 6 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its Australian distributor, Bayer Animal Health, a division of Bayer Australia Limited, has entered into an exclusive supply agreement with Angus Australia. Under the agreement, Bayer will supply Bioniche cattle reproductive products on an exclusive basis to the breed society for a three-year period. The Angus Association has a goal of facilitating the production of world-leading Angus genetics and branded beef.

    Bioniche signed a distribution agreement with Bayer Animal Health for the distribution of two Bioniche cattle reproduction products in June of this year. Under the agreement, Bayer Animal Health became the exclusive distributor of Bioniche's Cue-MateTM and PregnecolTM products in Australia. Cue-MateTM and PregnecolTM are high quality products with a proven track record in delivering consistent results and enhancing reproductive performance in both beef and dairy cattle. These are the products that will be supplied to Angus Australia.

    More than 1,300 cows have now been artificially inseminated using the Bioniche products through the "Angus Sire Benchmarking Project" run by Angus Australia. Bob Dent, Project Co-ordinator, said, "We expect to shortly reach our target of 2,000 cattle programmed and inseminated using a one-cycle artificial insemination (AI) program in commercial herds. This is the largest sire progeny test programme ever launched in Australia and the members who have nominated bulls will gain great benefits from their involvement. Bioniche and Bayer have provided technical advice and personnel to ensure that we receive maximum benefit from the work that we have put into the AI activities."

    "The agreement with Angus Australia is an indicator of the strength of our relationship with Bayer Animal Health in Australia," said Andrew Grant, Divisional President of Bioniche Animal Health Export Sales, Europe and A/Asia. "Angus Australia's commitment to the exclusive use of the Bioniche reproductive products distributed by Bayer provides recognition of the quality of these products and their perceived value in Angus Australia's artificial insemination programme."

    PregnecolTM is a well-established pregnant mare serum gonadotrophin (PMSG) - or equine chorionic gonadotrophin (eCG) - choice of veterinarians and producers in Australia, and Bioniche is the only supplier of domestically sourced and manufactured product. Cue-MateTMoffers an efficient and flexible progesterone treatment system, using specially designed treatment pods that attach to a reusable "wishbone" carrier system to deliver the progesterone for maximum effect. Cue-MateTM is the estrus synchronization device of choice for a growing number of Australian farmers.
  9. bionerd 22 december 2010 22:11
    Corporate News Release
    Bioniche Animal Health and IMV Technologies Sign European Distribution Agreement

    21/12/10

    agreement also provides market planning support for India

    BELLEVILLE, ON, Dec. 21 - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its Animal Health division has signed an agreement with IMV Technologies (France) for the exclusive distribution of a Bioniche cattle reproduction product and a select group of embryo transfer media products in Europe (excluding Spain, the UK and Ireland). This agreement extends to India, where IMV will assist Bioniche in the development of marketing plans for that jurisdiction.

    "This alliance provides Bioniche Animal Health with enhanced access to the rapidly expanding cattle reproduction market in continental Europe," said Andrew Grant, Divisional President of Bioniche Animal Health Export Sales, Europe and A/Asia. "This relationship will allow us to sell our Folltropin®-V and embryo transfer media products in a more streamlined fashion, with IMV Technologies having an established presence and renowned expertise in animal reproduction."

    "We look forward to this alliance in Europe where the in vitro fertilization segment is receiving growing interest from the industry," said Olivier Couture, VP, Marketing (Bovine) with IMV Technologies. "The association of IMV, the world leader in animal health biotechnology, with Bioniche Life Sciences, an expert in the pharmaceutical management of cattle reproductive performance, will provide the embryo transfer specialist with unparalleled support. The prospect of this alliance is particularly attractive in India where IMV Technologies' subsidiary is a respected market leader for the artificial insemination industry of the number one milk producer in the world, involving 40 million dairy cows and 90 million buffalo."

    About Folltropin®-V
    Folltropin®-V induces superovulation in cattle to facilitate embryo transfer. Embryo transfer permits a more rapid improvement of herd quality as compared to conventional breeding techniques. Folltropin®-V is the leading global follicle stimulating agent (70% market share) that induces superovulation in cattle to facilitate embryo transfer.

    About Bioniche's Embryo Transfer Media Products

    Successful embryo transfer requires not only hormones, but a variety of media and other supplies. Media, including the Company's ViGRO™ and SYNGRO® media are manufactured at the Company's manufacturing facility in Pullman, Washington, U.S.A.

    About IMV Technologies

    IMV Technologies is based in Normandy, France, with five subsidiaries located in Italy, the Netherlands, the U.S., China, and India. The company conceptualizes, engineers and markets instruments and technologies covering the entire gamut of operations linked to artificial reproduction, embryo transfer and cryopreservation of gametes, both for animals and humans. Through artificial insemination techniques for animals and the application of their technology, IMV Technologies both contributes to, and participates in, the improvement of animal species and the preservation of genetic heritage.

    Based in the heart of Normandy, 80% of IMV Technologies' sales are generated internationally and in more than 120 countries. Their development is based on perfecting new technologies which answer the growing needs of our customers' genetic development programs. Innovators by nature, IMV Technologies constantly develops new know-how for artificial insemination techniques, embryo transfer, bio-repositories and blood banking, all of which have multiple applications for humankind. To that end, their advances in the area of Assisted Reproduction Techniques, aimed at resolving human infertility issues, confirm the technological choices they have made and the commitment of an ever-growing list of customers to products of the highest standard quality.

  10. [verwijderd] 22 december 2010 22:32
    Is een bericht van gisteren nabeurs.
    De koers heeft er vandaag nauwelijks op gereageerd met plus 3,5% naar CAD 1,49.
    Op 6 december een soortgelijk bericht betr. distributie van een zelfde product in Australië via Bayer, ook nauwelijks koersreactie.
    Veterinaire zaken spreken de beleggers blijkbaar niet aan.

    Het wachten is op de uitkomst van het Urocidin FaseIII onderzoek bij Endo.

    Bioniche has developed a technology for the treatment of human cancers. The first product developed from this technology is Urocidin™, a formulation of Mycobacterial Cell Wall-DNA Complex (MCC) for the treatment of bladder cancer. A Phase III clinical program is underway, in partnership with Endo Pharmaceuticals Inc.

  12. [verwijderd] 4 januari 2011 12:34
    Was Fase 3A niet reeds positief afgesloten, waarop een milestone payment van € 4 mio van Endo volgde.

    Hieronder nog even het oude nieuws uit november 2010, zoals bekend neemt Endo alle kosten van de ontwikkleing op zich, en kan BNC in totaal € 110 mio verwachten bij positieve resultaten.

    GEN news highlights: Nov 17, 2010

    Bioniche Earns $4M Milestone from Endo following Positive Phase III Urocidin Data

    Bioniche Life Sciences earned a $4 million milestone payment from its global licensee Endo Pharmaceuticals on the back of positive one-year data from a registrational trial evaluating Urocidin™ in the treatment of nonmuscle-invasive bladder cancer that is refractory to current first-line therapy with Bacillus Calmette-Guérin (BCG). The product is a formulation of Bioniche’s mycobacterial cell wall-DNA complex (MCC), which is a cell wall-DNA composition prepared from a culture of the bacterium Mycobacterium phlei.

    The firms state they expect to start a new, larger Phase III trial with Urocidin before the end of 2010. The completed Phase III study included 105 patients, and the new trial will include about 450 patients, and compare Urocidin with mitomycin C for the intravesical treatment of recurrent or refractory nonmuscle-invasive bladder cancer.

    Bioniche says it has now received four milestones from Endo as part of their Urocidin deal. The original agreement, signed in 2009, gave Endo exclusive rights to the drug for the U.S. market, and an option to global rights. This option was exercised in February 2010, at which point Endo took on the responsibility for all future costs associated with development of the drug worldwide. Bioniche could receive up to $110 million in clinical, regulatory and commercial milestones.

    Bioniche claims MCC has a dual mode of action that both directly induces apoptosis in cancer cells and stimulates anticancer cytokine production by immune effector cells. The firm is initially focused on developing MCC for a range of cancers. In addition to its lead bladder cancer product, MCC candidates are also in preclinical development against prostate tumors, muscle-invasive bladder cancer, ovarian and colorectal cancers, melanoma, osteosarcoma, and metastatic breast and colon cancers. Phase I trials in prostate cancer have been completed.
  13. bionerd 4 januari 2011 17:12
    Fase IIIa succesvol afgesloten maar de resultaten zijn nog niet gepubliceerd door ENDO. Laatste melding was. Results will be published shortly. Dit is al weer een week of 6 geleden.

    De vraag is: (lees trigger) zijn de resultaten net zo goed als fase II. Indien ja, dan zal de koers substantieel omhoog gaan.

    Het wachten is dus op ENDO.

  14. [verwijderd] 11 januari 2011 18:40
    Nou, nou ...

    "low quality company"
    "overvaluation"
    "likely to underperform the market"

    Toch een verkeerde gok geweest ?

    "Positive Outlook", dat dan weer wel.

    SADIF Analytics releases new summary due diligence report for Bioniche Life Sciences

    2011-01-10 13:17:56 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Bioniche Life Sciences and produced a report, rating the company's attractiveness to long-term investors.

    Ilhavo, Portugal – SADIF Investment Analytics, announces a new summary due diligence report covering Bioniche Life Sciences (BNC). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Bioniche Life Sciences investor.

    Report Summary: Bioniche Life Sciences is a low quality company with a positive outlook. Bioniche Life Sciences has weak business growth
    and is run by efficient management. The trend in Bioniche Life Sciences fair value exchange rate against its closest rated-competitor, IBEX Technologies, Inc., has been depreciating over the past 2 weeks. When compared to its closest competitor, Bioniche Life Sciences shows similar overvaluation and is equally likely to underperform the market.

    The 10-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Bioniche Life Sciences for long-term investors.

    The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
    www.sadifanalytics.com/stockmarks/com... ..

    About SADIF-Investment Analytics:
    SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.
  15. bionerd 17 februari 2011 18:44
    tweede fase III is begonnen, maar er worden door ENDO nog immer geen details vrijgegeven over Fase IIIa.... Deze resultaten kunnen de enige trigger zijn voor een koerssprong. Ik heb zelf mijn positie de afgelopen dagen uitgebouwd. Blijf vertrouwen hebben in een goede afloop.

    In its Australian PR, McRae said that more than 1 milestone to come soon

    “We are also soon expecting to reach a number of near term milestones, including sharing results of a Phase III clinical trial for our therapeutic targeting human bladder cancer (Urocidin™) that continues its Phase III clinical program with a US commercial partner."

    450 patients to be enrolled at approximately 120 global sites

    CHADDS FORD, PA, and BELLEVILLE, ON, Feb. 16 /CNW/ - Endo Pharmaceuticals (Nasdaq: ENDP) and Bioniche Life Sciences Inc. (Toronto:BNC.TO), today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin™. The trial is a randomized, active-controlled, open-label, multi-center study with a blinded endpoint assessment designed to compare Urocidin™ with mitomycin C in the intravesical treatment of patients with BCG recurrent or refractory non-muscle-invasive bladder cancer.

    It is estimated that 450 patients will be enrolled for this new trial at approximately 120 clinical sites worldwide. Summary details of the study protocol are now publicly available via the U.S. National Institutes of Health (NIH) clinical trial registration service at www.clinicaltrials.gov.

  16. bionerd 18 februari 2011 15:40
    UROCIDIN™ PHASE III CLINICAL TRIAL RESULTS TO BE PRESENTED AT EAU AND AUA CONFERENCES
    Feb. 17, 2011 (Canada NewsWire Group) --
    -overall one-year disease-free survival rate of 25 percent
    in treatment-refractory non-muscle-invasive bladder cancer-

    CHADDS FORD, PA. and BELLEVILLE, ON, Feb. 17 /CNW/ - Endo Pharmaceuticals (Nasdaq: ENDP) and Bioniche Life Sciences Inc. (TSX and ASX: BNC) today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348. The results to be presented have been generated from an ongoing Phase III registration trial with Urocidin™ in the treatment of non-muscle-invasive bladder cancer (NMIBC) that is refractory to current first-line therapy (Bacillus Calmette-Guérin, known as BCG).

    The first abstract and poster summaries of such results will be made available during the Annual Congress of the European Association of Urology (EAU) March 18-22 in Vienna, Austria. The accepted abstract is now available to EAU members. Further disclosure of results from this trial will be made during a podium presentation at the annual American Urological Association (AUA) meeting May 14-19 in Washington, D.C.

    Phase III Results

    The EAU and AUA abstracts highlight results based on an interim analysis of the Phase III trial. The objective of the trial is to evaluate the efficacy and safety of Urocidin™ in patients with non-muscle-invasive bladder cancer (NMIBC) who are refractory to intravesical BCG therapy and at high risk of progression. A total of 129 patients were enrolled from 25 centers in the U.S. and Canada, with high grade papillary and/or carcinoma in situ (CIS) and having failed to respond to one or more courses of BCG. The overall one-year disease-free survival (DFS) rate was 25 percent. DFS is defined as lack of recurrence or progression to muscle-invasive disease, as confirmed by biopsy. The one-year DFS rates, when sub-divided by tumor type (e.g., CIS with or without papillary tumors or papillary tumors alone) at study entry is disclosed in the conference materials, as is the median DFS interval (in days) of the intent-to-treat population. In terms of safety, the results showed that intravesical administration of Urocidin™ was well tolerated, with most adverse events being mild to moderate in severity and few leading to discontinuation of treatment. The authors of the abstract concluded that the interim analysis of this prospective trial indicates that Urocidin™ may provide an alternative to cystectomy for patients with BCG-refractory NMIBC.

    Ongoing Phase III Clinical Program with UrocidinTM

    Summary details of a second Phase III clinical trial protocol being conducted by Endo are publicly available via the U.S. National Institutes of Health (NIH) clinical trial registration service at www.clinicaltrials.gov.

79 Posts
Pagina: «« 1 2 3 4 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 873,21 -0,18%
EUR/USD 1,0690 -0,12%
FTSE 100 8.040,33 -0,06%
Germany40^ 18.064,10 -0,41%
Gold spot 2.334,52 +0,54%
NY-Nasdaq Composite 15.696,64 +1,59%

Stijgers

VIVORY...
+14,58%
ASMI
+11,85%
NX FIL...
+4,97%
BESI
+3,97%
FASTNED
+3,25%

Dalers

ALLFUN...
-10,63%
ING
-6,10%
WDP
-2,81%
AZERION
-2,35%
Flow T...
-2,34%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!